FDA approves first drug tests for treatment of West Nile virus
NEW YORK -- The Food and Drug Administration has approved the first national trial of a drug to treat the West Nile virus, which has spread across half the country and killed at least 31 people since it was first detected in the United States three years ago.
The testing of alpha-interferon will begin immediately at New York Hospital Queens, in the borough where the mosquito-borne virus was first found in the country.
James Rahal, the study's chief investigator, said the trial will enroll 40 people 50 and older who have been hospitalized with the virus. Patients across the country can enroll, but the trial most likely will focus on Louisiana and Mississippi, where at least 10 West Nile deaths have been confirmed this year.
Rahal said the length of the trial depends on the results.
Alpha-interferon is already sold by Schering-Plough as Intron A for treatment of hepatitis C.
Laboratory tests have shown interferon to be effective in lessening the symptoms and length of hepatitis in infected patients. It has also proven effective against St. Louis encephalitis, a virus similar to West Nile.
Rahal said Wednesday that he treated 15 Louisiana patients with the drug in a study to make sure it was safe for people with West Nile.
He said the results were promising enough to get the FDA to approve the new trial. "Encouraging," he said. "Not convincing, but encouraging."
The West Nile virus is passed on to humans by mosquitos that have bitten infected birds. Government researchers say less than 1 percent of people who are bitten will become severely ill.
Those who do suffer flu-like symptoms and, in the worst cases, encephalitis, a potentially fatal brain inflammation.
The study will treat patients whose virus is still in the blood, where it circulates before entering the brain, Rahal said. Therefore, patients must begin treatment within four days of being admitted.
"Once damage has occurred in the brain, it's not likely to be reversible, at least not by a drug," Rahal said. "What we want to do is increase the body's defense against the virus, and decrease the amount of virus that ultimately enters the brain or the nervous system."